Ranolazine is an approved drug for the treatment of angina and is another example of a multiple-ion channel blocker (hERG IC50 = 6490 nM; Nav-late IC50 = 7884 nM) that is not arrhythmogenic, despite causing QT-prolongation due to hERG inhibition. Here, KCNH2 is linked to angina pectoris.